

Regd. Office :

'Zydus Tower',
Satellite Cross Roads,
Ahmedabad 380 015. India.
Phone : +91-79-2686 8100 (20 Lines)
Fax : +91-79-2686 2368
www.zyduscadila.com
CIN:L24230GJ1995PLC025878

<p>BSE Limited 1st Floor, P.J. Towers Dalal Street <u>Mumbai – 400 001</u></p> <p>Kind Attn.: Mr. Sanjay Golecha / Mr. Gopalkrishnan</p>	<p>National Stock Exchange of India Limited Exchange Plaza, 5th Floor, Plot No. C/1, G Block, Bandra-Kurla Complex, Bandra (East) <u>Mumbai – 400 051</u></p> <p>Kind Attn.: Famroze Pochara Asst. Vice President</p>
<p>Date: June 1, 2016</p>	
<p>Re.: Press Release.</p>	

Dear Sir / Madam,

We enclose herewith a copy of press release dated June 1, 2016 under the title **Zydus receives final approval from the USFDA for Amantadine Hydrochloride Capsules** which will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad. The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors' at large.

Thanking you,

Yours faithfully,
For **Cadila Healthcare Limited**


Upen H. Shah
Company Secretary



Encl.: As above.

Zydus receives final approval from the USFDA for Amantadine Hydrochloride Capsules

Ahmedabad, 01 June 2016

Zydus Cadila has received the final approval from the USFDA to market Amantadine Hydrochloride Capsules USP, 100 mg.

The estimated sales for Amantadine Hydrochloride Capsules USP as per IMS (*MAT April 2016*) is USD 40.1 million. The drug which is used in the treatment of Parkinson's disease and select viral infections, will be produced at the group's formulations manufacturing facility at the Pharma SEZ in Ahmedabad.

The group now has more than 100 approvals and has so far filed nearly 270 ANDAs since the commencement of the filing process in FY 2003-04.
